Amylon™ LLC’s mission is to finance, develop and commercialize APH-1104 for mild to moderate Alzheimer’s disease and other CNS disorders.
Alzheimer’s disease (AD) is a widespread and significant neurological disorder that affects more than 4.5 million Americans and more than 10 million people worldwide. Current drugs only treat the symptoms of AD, none of these medications is a cure for the disease. All recent clinical trials for AD have failed. Our strategy is to reverse the course of the disease by up-regulating a key enzyme that both prevents and reduces Aβ plaques in AD.